Technical Analysis for ALRN - Aileron Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 1.505 -7.10% -0.12
ALRN closed up 22.73 percent on Friday, May 29, 2020, on 4.51 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical ALRN trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish -7.10%
Pocket Pivot Bullish Swing Setup -7.10%
Volume Surge Other -7.10%
New 52 Week High Strength -7.10%
Parabolic Rise Strength -7.10%
Upper Bollinger Band Walk Strength -7.10%
Wide Bands Range Expansion -7.10%
Above Upper BB Strength -7.10%
Overbought Stochastic Strength -7.10%
Up 3 Days in a Row Strength -7.10%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Biopharmaceutical Cancer Biology Solid Tumors Cancers Inflammation Molecular Biology Tumor Cell Biology Proteins Metabolic Diseases Oncogenes Lymphomas P53 Tumor Suppressor Tumor Suppressor Genes

Is ALRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 1.63
52 Week Low 0.25
Average Volume 640,236
200-Day Moving Average 0.60
50-Day Moving Average 0.57
20-Day Moving Average 0.74
10-Day Moving Average 0.91
Average True Range 0.14
ADX 39.49
+DI 51.38
-DI 4.54
Chandelier Exit (Long, 3 ATRs ) 1.21
Chandelier Exit (Short, 3 ATRs ) 0.88
Upper Bollinger Band 1.30
Lower Bollinger Band 0.18
Percent B (%b) 1.28
BandWidth 151.74
MACD Line 0.19
MACD Signal Line 0.10
MACD Histogram 0.0865
Fundamentals Value
Market Cap 23.84 Million
Num Shares 14.7 Million
EPS -41.73
Price-to-Earnings (P/E) Ratio -0.04
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.94
Resistance 3 (R3) 1.90 1.77 1.88
Resistance 2 (R2) 1.77 1.69 1.78 1.86
Resistance 1 (R1) 1.69 1.64 1.73 1.73 1.85
Pivot Point 1.56 1.56 1.58 1.57 1.56
Support 1 (S1) 1.48 1.48 1.52 1.52 1.39
Support 2 (S2) 1.35 1.43 1.36 1.38
Support 3 (S3) 1.27 1.35 1.36
Support 4 (S4) 1.31